The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Innovent will supply sintilimab for the collaborated clinical trial
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
NEIAFMR to be developed as the national hub for folk medicine
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
US FDA approval based on NEURO-TTRansform Phase III results
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
